Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca AB
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
Study to evaluate if dapagliflozin treatment is effective in heart failure by reducing the number of hospitalizations due to heart failure, or worsening of heart failure events, and to improve the survival for patients with heart failure Badanie oceniające skuteczność leczenia dapagliflozyną u chorych z niewydolnością serca na podstawie zmniejszenie liczby hospitalizacji lub nasilenia objawów niewydolności serca oraz wydłużenia czasu przeżycia pacjentów z niewydolnością serca
To determine whether dapagliflozin is superior to placebo, when added to standard of care, in reducing the incidence of CV death or a HF event (hospitalization for HF or equivalent HF event, ie an urg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to an Antidepressant Treatment (ONYX STUDY)
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate sustained release in combination with an antidepressant versus an antidepressant alone in patients with Major Dep...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell Lung Cancer who Have Failed One Prior Platinum-based Chemotherapy Regimen
To demonstrate an improvement in survival for the combination of ZD4054 plus pemetrexed compared to pemetrexed alone in patients with locally advanced or metastatic NSCLC without predominantly squamou...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A PhII to Evaluate the efficacy, safety and tolerability of AZD5069 in Patients with Uncontrolled Persistant Asthma
To determine the efficacy of 3 different doses of AZD5069 compared with placebo on the rate of severe asthma exacerbations over 6 months in adults with uncontrolled persistent asthma, despite treatmen...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 2-week, randomised, double-blind, placebo-controlled, parallel group study to assess the tolerability and pharmacokinetics of orally administered AZD9668 in patients with COPD
1. To investigate the tolerability of 14 days’ dosing with AZD9668 in patients with COPD, as measured by vital signs, ECG, lung function, haematology, clinical chemistry, urinalysis and adverse event ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)
To demonstrate an improvement in overall survival for ZD6474 (ZACTIMA™ ) plus best supportive care (BSC) compared with placebo plus BSC in patients with locally advanced or metastatic NSCLC after prio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A phase II, double-blind, placebo-controleed, randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with hormone refractory prostate cancer (HRPC)
To assess the efficacy of ZD6474 in combination with docetaxel/prednisolone in the treatment of HRPC by the rate of prostate specific antigen (PSA) fall.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography (MSCT) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to evaluate structural changes effected by AZD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography (qEEG) and Event-Related Potentials (ERP) in Patients with Mild-to-Moderate Alzheimer's Disease
To evaluate the effect of single and multiple dosing of AZD1446 and a single dose of donepezil on Quantified electroencephalography (qEEG) and Event-related potentials (ERP) in patients with mild-to-m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 16-Week Randomized, Double-blind, Parallel-group, Multicentre, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes
The primary objective of this study is to determine the efficacy of tesaglitazar given as monotherapy as compared to placebo in patients with type 2 diabetes in improving whole body insulin sensitivit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
15
16
17
18
19
20
21
22
23
24
Suivant